Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 1.00 |
| ▸ | NPC1 | O15118 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.72 |
| ▸ | POLB | P06746 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11115961 | 0.84 | RAB9A (1.00) | RAB9ANPC1KMT2AKDM4EPOLB | |
| SCHEMBL3804620 | 0.82 | RAB9A (0.74) | RAB9ANPC1KMT2AKDM4EPOLB | |
| SCHEMBL14517928 | 0.80 | RAB9A (0.72) | RAB9ANPC1KMT2AKDM4EPOLB | |
| SCHEMBL14517930 | 0.80 | KDM4E (1.00) | RAB9ANPC1KMT2AKDM4EPOLB | |
| SCHEMBL23987239 | 0.79 | RAB9A (0.75) | RAB9ANPC1KMT2AKDM4EPOLB | |
| SCHEMBL5381046 | 0.79 | KDM4E (0.69) | RAB9ANPC1KMT2AKDM4EPOLB | |
| SCHEMBL19707622 | 0.79 | RAB9A (0.76) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL10951643 | 0.79 | NPC1 (0.71) | RAB9ANPC1KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL2789615 | 0.79 | RAB9A (0.64) | RAB9ANPC1KMT2AKDM4EPOLB | |
| SCHEMBL27578667 | 0.77 | RAB9A (0.74) | RAB9ANPC1KMT2AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329863-A1 | NOVEL ANTIPRION COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329863-A1 | NOVEL ANTIPRION COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-06 | — | — | US | disclosed |
| WO-2013033037-A2 | NOVEL ANTIPRION COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140329863-A1 | NOVEL ANTIPRION COMPOUNDS | PRNP, PSEN1, PSEN2 | RAB9A 1779/4885NPC1 57/4885KMT2A 4582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.